The Lead Podcast presented by Heart Rhythm Society

In this episode of The Lead, host Robert Schaller, DO, FHRS, is joined by Tina Baykaner, MD, MPH, and Maulin Shah, MD, to discuss the journal article, Device-Related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-Term Follow-Up: The PRAETORIAN-XL Trial. Together, they review the study's long-term follow-up findings and explore device-related complications associated with transvenous and subcutaneous defibrillator therapy.
 
Learning Objectives:
Review the long-term follow-up results of the PRAETORIAN-XL Trial comparing transvenous and subcutaneous defibrillator therapy.
Discuss device-related complications associated with transvenous and subcutaneous implantable defibrillator systems.
Examine the clinical considerations of defibrillator therapy selection based on long-term device-related outcomes.
 
Host: Robert Schaller, DO, FHRS 
Guests: Tina Baykaner, MD, MPH and Maulin Shah, MD
 
Disclosures:
 
R. Schaller
Honoraria/Speaking/Consulting Fee: Philips, Abbott Medical
Officer/Trustee/Director/Committee Chair/Other Fiduciary Role: Imricor
Other Financial Relationship: Other
 
T. Baykaner
Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific
Research: NIH, Boston Scientific
 
M Shah
No relevant disclosures

In this episode of The Lead, host Sandeep A. Saha, MD, MS, FHRS, is joined by Suraj Kapa, MD, FHRS, and Albert Joseph Rogers, BSE, MBA, MD, FHRS, to discuss the journal article, Predicting Sudden Cardiac Death in Patients With Sarcoidosis Using a Multimodal Artificial Intelligence Model. Together, they review the study's approach to using a multimodal artificial intelligence model to predict sudden cardiac death risk in patients with sarcoidosis and discuss the potential implications of these findings.
Learning Objectives
Review the methodology and key findings of a multimodal artificial intelligence model developed to predict sudden cardiac death in patients with sarcoidosis.
Discuss the potential role of artificial intelligence–based risk prediction in the evaluation of patients with sarcoidosis.
Examine the clinical implications of sudden cardiac death risk stratification in this patient population.
Host: Sandeep A Saha, MD, MS, FHRS
Guests: Suraj Kapa, MD, FHRS and Albert Joseph Rogers, BSE, MBA, MD, FHRS
 
Disclosures:
Sandeep A Saha, MD, MS, FHRS
•       Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Medtronic, Inc.
 
Suraj Kapa, MD, FHRS
•       Honoraria/Speaking/Consulting Fee: Abbott
•       Stock Options: Nanowear Inc.
•       Other Non-Financial Relationships: Biosense Webster, Inc., Boston Scientific
 
Albert Joseph Rogers, BSE, MBA, MD, FHRS
•       Research: National Institutes of Heath, American Heart Association
•       Ownership/Partnership: WearLinq, Inc.
•       Honoraria/Speaking/Consulting Fee: Other

In this episode of The Lead, host Christopher Kowalewski, MD, is joined by John M. Mandrola, MD, and Nassir F. Marrouche, MD, FHRS, to discuss the journal article, The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial. Together, they explore the relationship between atrial fibrillation burden and quality of life, reviewing findings from this substudy of the SHAM-PVI Trial and discussing their relevance to patient-centered outcomes.
Learning Objectives
Review the key findings from the SHAM-PVI Trial substudy examining the association between atrial fibrillation burden and quality of life.
Discuss the relationship between atrial fibrillation burden and patient-reported quality-of-life outcomes.
Explore the implications of assessing both arrhythmia burden and quality of life when evaluating treatment outcomes in atrial fibrillation.
 
Host: Christopher Kowalewski, MD
Guests: John M. Mandrola, MD and Nassir F. Marrouche, MD, FHRS
 
Disclosures:
Christopher Kowalewski, MD
No relevant disclosures
 
John M. Mandrola, MD
No relevant disclosures
 
Nassir F. Marrouche, MD, FHRS
•       Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Biosense Webster, Inc., Boston Scientific, AtriCure, Inc., Abbott, Sanofi
•       Research: Abbott, Biosense Webster, Inc., Medtronic, Siemens, General Electric, Boston Scientific, Sanofi, Samsung

In this episode of The Lead, host Christopher C. Cheung, MD, MPH, FHRS, is joined by Edward P. Gerstenfeld, MD, MS, FHRS, and Paul C. Zei, MD, PhD, FHRS, to discuss the journal article, A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD). Together, they review the study design and findings, examining pulsed field ablation and anti-arrhythmic drug therapy as first-line treatment approaches for patients with persistent atrial fibrillation.
Learning Objectives
Review the design and key findings of the AVANT GUARD study comparing pulsed field ablation with anti-arrhythmic drug therapy as first-line treatment for persistent atrial fibrillation.
Discuss the potential role of pulsed field ablation as an initial treatment strategy for patients with persistent atrial fibrillation.
Examine the comparative considerations of ablation-based and pharmacologic approaches in the management of persistent atrial fibrillation.
 
Podcast Contributors:
Host: Christopher C Cheung, MD, MPH, FHRS      
Guests: Edward P. Gerstenfeld, MD, MS, FHRS and Paul C Zei, MD, PhD, FHRS
 
Disclosures:
Christopher C Cheung, MD, MPH, FHRS
Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biotronik, Biosense Webster, Inc., Abbott
Edward P. Gerstenfeld, MD, MS, FHRS
Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Abbott, Boston Scientific, Varian Medical Systems
Other Non-Financial Relationships: Adagio Medical, Boston Scientific, Abbott Medical
Research: Abbott Medical
Officer, Trustee, Director, Committee Chair, or Other Fiduciary Role: American College of Cardiology
Paul C Zei, MD, PhD, FHRS
Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Varian Medical Systems, Biosense Webster, Inc., Abbott, Boston Scientific, APT Medical
Research: Biosense Webster, Inc.

In this episode of The Lead, host Sandeep A. Saha, MD, MS, FHRS, is joined by Babak Nazer, MD, and Rajesh Kabra, MD, FHRS, to discuss the journal article, Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6-Month Results of the FlexPulse IDE Study. Together, they review the study's six-month findings and explore the safety and effectiveness of a dual-energy focal ablation catheter for the treatment of paroxysmal atrial fibrillation.
Learning Objectives
Review the six-month results of the FlexPulse IDE Study evaluating a dual-energy focal ablation catheter for the treatment of paroxysmal atrial fibrillation.
Discuss the safety outcomes reported in the study and their implications for clinical practice.
Examine the effectiveness findings of the dual-energy focal ablation approach in patients with paroxysmal atrial fibrillation.
Podcast Contributors

Sandeep A Saha, MD, MS, FHRS 
Babak Nazer, MD
Rajesh Kabra, MD, FHRS
 
Host and Contributor Disclosure(s):

S. Saha
• Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Medtronic, Inc.
B. Nazer

•Honoraria/Speaking/Consulting Fee: Edwards Lifesciences, Biosense Webster, Inc., Siemens Healthineers •Research: Siemens Healthineers
R. Kabra
•Honoraria/Speaking/Consulting Fee: AtriCure, Inc., Biosense Webster, Inc., Milestone Pharmaceuticals, AltaThera Pharmaceuticals
•Research: Abbott Medical, Medtronic, Inc.